Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Protesters against war in Gaza interrupt Blinken repeatedly in the Senate
Yvette Fielding says her Most Haunted co
The fightback begins: Boss of London's Queen Mary University tells pro
Kristin Cavallari, 37, ignores critics of her age
'IF' movie review: John Krasinski’s film hits a box office nerve with $35 million debut
Kristin Cavallari, 37, ignores critics of her age
The unstoppable duo of Emma Stone and Yorgos Lanthimos
A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
At least 40 villagers shot dead in latest violence in Nigeria's conflict
Yvette Fielding says her Most Haunted co
Tennessee latest state to mandate automatic defibrillators at high schools
‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad